Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque Psoriasis
NCT05739435
·
clinicaltrials.gov ↗
PHASE2
Phase
ACTIVE_NOT_RECRUITING
Status
165
Enrollment
INDUSTRY
Sponsor class
Conditions
Plaque Psoriasis
Interventions
DRUG:
envudeucitinib
Sponsor
Alumis Inc